Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFS Provident Financial Services Inc

盘前交易 07-09 07:16:16 EDT

18.73

+0.15

+0.81%

最高19.03	最低18.61	成交量45.67万
今开18.64	昨收18.58	日振幅2.26%
总市值24.47亿	流通市值23.63亿	总股本1.31亿
成交额859.04万	换手率0.36%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":18.73,"timestamp":1752004800000,"preClose":18.58,"halted":0,"volume":456734,"delay":0,"floatShares":126185309,"shares":130659942,"eps":1.188092,"marketStatus":"盘前交易","change":0.15,"latestTime":"07-09 07:16:16 EDT","open":18.64,"high":19.025,"low":18.605,"amount":8590435.7656,"amplitude":0.022605,"askPrice":20.51,"askSize":100,"bidPrice":16.98,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752067800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":18.745,"dividendRate":0.051255,"postHourTrading":{"tag":"盘后","latestPrice":18.73,"preClose":18.73,"latestTime":"16:11 EDT","volume":23436,"amount":438956.28,"timestamp":1752005516817},"volumeRatio":0.765314962354621,"impliedVol":0.2798,"impliedVolPercentile":0.5984},"requestUrl":"/m/hq/s/PFS","defaultTab":"news","newsList":[{"id":"2548394331","title":"【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经","url":"https://stock-news.laohu8.com/highlight/detail?id=2548394331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548394331?lang=zh_cn&edition=full","pubTime":"2025-07-04 22:34","pubTimestamp":1751639654,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU1169590202.USD","BK4097","BK4195","BK7095","ORR.AU","BK4134","BK4211","ORR","PD","OS","LU1169589451.USD","PFS","BK4023","HCC","BK4006","02616","III","BK1574"],"gpt_icon":0},{"id":"2546485753","title":"公积金金融服务盘中异动 下午盘快速拉升5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546485753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546485753?lang=zh_cn&edition=full","pubTime":"2025-06-27 01:33","pubTimestamp":1750959202,"startTime":"0","endTime":"0","summary":"北京时间2025年06月27日01时33分，公积金金融服务股票出现异动，股价大幅上涨5.09%。截至发稿，该股报17.76美元/股，成交量31.8422万股，换手率0.24%，振幅4.20%。公积金金融服务股票所在的银行行业中，整体涨幅为0.93%。该公司的业务仅限于金融服务行业，包括向客户提供传统银行和其他金融服务。该公司有一个单一报告部门用于财务报告目的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627013322a4bf8dfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627013322a4bf8dfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2546853758","title":"Provident Finl Servs(PFS.US)获雷蒙德詹姆斯公司首次覆盖，给予强烈买入评级, 目标价21.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2546853758","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546853758?lang=zh_cn&edition=full","pubTime":"2025-06-27 00:13","pubTimestamp":1750954399,"startTime":"0","endTime":"0","summary":"Provident Finl Servs(PFS.US)获雷蒙德詹姆斯公司首次覆盖，给予强烈买入评级, 目标价21.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/27001351332351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PFS"],"gpt_icon":0},{"id":"2546730165","title":"Provident Finl Servs(PFS.US)获雷蒙德詹姆斯公司首次覆盖，给予强烈买入评级, 目标价21.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2546730165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546730165?lang=zh_cn&edition=full","pubTime":"2025-06-27 00:09","pubTimestamp":1750954181,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2546227969","title":"【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2546227969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546227969?lang=zh_cn&edition=full","pubTime":"2025-06-26 08:26","pubTimestamp":1750897582,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4211","02256","BK4006","03347","PFS","HCC","LU2488822045.USD","BK1574","BK1583","399441","BK1515","ORR","BK1576","BK1141","159938","BK4195","09939","BK1161","161726"],"gpt_icon":0},{"id":"2545424700","title":"FDA批准Monjuvi用于复发性、难治性滤泡性淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2545424700","media":"亿欧网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545424700?lang=zh_cn&edition=full","pubTime":"2025-06-24 09:27","pubTimestamp":1750728421,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Monjuvi（tafasitamab-cxix），一种人源化的Fc修饰溶细胞CD19靶向单克隆抗体，用于治疗复发或难治性滤泡性淋巴瘤的成年患者。该批准基于3期临床试验inMIND的结果，该试验显示，与安慰剂组相比，Monjuvi组在无进展生存期（PFS）方面取得了具有统计学意义和临床意义的显著改善。然而，在接受Monjuvi联合利妥昔单抗和来那度胺治疗的患者中，有33%发生了严重不良反应，包括严重感染、肾功能不全、第二原发恶性肿瘤以及发热性中性粒细胞减少症。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ky.jrj.com.cn/2025/06/24092751254008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2544181398","title":"【基石药业-B(02616.HK)：舒格利单抗GEMSTONE-302长期生存数据再登《柳叶刀•肿瘤学》】智通财经APP","url":"https://stock-news.laohu8.com/highlight/detail?id=2544181398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544181398?lang=zh_cn&edition=full","pubTime":"2025-06-19 08:15","pubTimestamp":1750292155,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK1574","OS","BK4097","BK4195","BK4211","PFS","BK1161","BK4134","02616"],"gpt_icon":0},{"id":"2542595338","title":"葆元医药母公司Nuvation Bio宣布ROS1抑制剂己二酸他雷替尼获FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2542595338","media":"医药时间","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542595338?lang=zh_cn&edition=full","pubTime":"2025-06-12 16:16","pubTimestamp":1749716169,"startTime":"0","endTime":"0","summary":"中国大陆地区商品名为达伯乐，在大中华区由Nuvation Bio的全资子公司葆元医药许可信达生物制药集团负责商业化运营。据估计，约2%的NSCLC患者携带ROS1阳性基因。关于Nuvation Bio和葆元医药Nuvation Bio是一家商业化阶段的全球性抗肿瘤生物制药公司，专注于攻克癌症治疗领域重大难题，进而对患者的生活产生深远的积极影响。葆元医药坐落于浙江省杭州市钱塘区中国医药港，在被Nuvation Bio于2024年4月收购后，成为Nuvation Bio的全资子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612161826a704d4f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612161826a704d4f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFS","DDC","CNS","ODD","BK4212","BK4183","BK4135","BK4007","BK4211","IE0009354923.USD","BK4195","NUVB"],"gpt_icon":0},{"id":"2542319892","title":"皮下注射“破局”，肿瘤治疗迎来“分钟级”变革","url":"https://stock-news.laohu8.com/highlight/detail?id=2542319892","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542319892?lang=zh_cn&edition=full","pubTime":"2025-06-10 18:59","pubTimestamp":1749553190,"startTime":"0","endTime":"0","summary":"6月7日，默沙东皮下注射版PD-1抑制剂帕博利珠单抗正式向中国药监局提交上市申请。这不仅是中国首款申报上市的皮下注射PD-1抗体，更意味着患者未来可能仅需2分钟就能完成抗癌治疗。Halozyme公司认为默沙东皮下注射K药侵犯了其相关专利。除了疗效相当，皮下注射在治疗效率和患者体验方面的优势也十分显著。在患者椅旁停留时间上，皮下注射组较静脉注射组锐减49.7%，从117.2分钟降至59.0分钟。在中国，肿瘤治疗药物的研发竞争也异常激烈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610192102a4a1e09e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610192102a4a1e09e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B1BXHZ80.USD","LU1162221912.USD","LU0106261372.USD","IE000M9KFDE8.USD","SG9999014567.USD","LU1066051811.HKD","LU0985320562.USD","LU1699723380.USD","BK4588","SG9999014559.SGD","LU0965508806.USD","IE00BLSP4452.SGD","BK4533","SG9999002224.SGD","LU0203347892.USD","LU1035773651.USD","LU1291159041.SGD","LU1093756325.SGD","BK4516","01877","LU0265550946.USD","LU0965509283.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU1934455194.USD","MRK","PFS","SG9999014542.SGD","LU1066051225.USD","LU0320765489.SGD","LU0211331839.USD","LU2112291526.USD","BK4195","LU2089984988.USD","SG9999014575.USD","IE00BN8TJ469.HKD","LU1983299246.USD","ORR","LU1934455863.HKD","IE00B2B36J28.USD","LU0203345920.USD","LU0238689110.USD","SG9999001440.SGD","SGXZ57979304.SGD","LU0289739699.SGD","LU2468319806.SGD","LU0265550359.USD","BK4550","LU0208291251.USD","LU1057294990.SGD","SG9999015358.SGD"],"gpt_icon":0},{"id":"2539589248","title":"医药行业研报：吉利德SG联合K药一线治疗PD-L1+ TNBC达到PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2539589248","media":"太平洋证券股份...","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539589248?lang=zh_cn&edition=full","pubTime":"2025-05-30 00:00","pubTimestamp":1748534400,"startTime":"0","endTime":"0","summary":"事件：近日，吉利德宣布III 期ASCENT-04 研究达到了PFS 主要终点。核心观点：SG联合K 药一线治疗PD-L1+ TNBC 头对头击败K 药+化疗，PFS 延长具有统计学和临床意义。PD-L1 阳性mTNBC的一线标准治疗为帕博利珠单抗联合化疗，中位PFS 为9.7 个月，mOS为23 个月。此外，SG 对比化疗在一线治疗 PD-L1 阴性TNBC的3 期临床ASCENT-03 也达到了PFS 主要终点。一线PD-L1 阴性TNBC 市场竞争激烈，主要竞品包括Dato、SKB264、BL-B01D1。另一方面，PDL1 阴性TNBC 市场面临激烈竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530144512976ac147&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530144512976ac147&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","IE00BLSP4452.SGD","LU1699723380.USD","SG9999014575.USD","BK4550","BK4139","IE00BFTCPJ56.SGD","BK4534","LU0106261372.USD","LU0965509010.AUD","LU2087621335.USD","BK4566","LU0211331839.USD","LU1929549753.HKD","IE00BSNM7G36.USD","LU2106854487.HKD","LU2361045086.USD","LU1934455863.HKD","PFS","BK4583","LU1037948541.HKD","LU0823416689.USD","LU2361044949.HKD","SG","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1989772840.SGD","LU0320765489.SGD","LU1162221912.USD","SGXZ57979304.SGD","BK4007","IE00BN8TJ469.HKD","LU1941712348.USD","LU1974910355.USD","LU0320765646.SGD","IE000M9KFDE8.USD","LU1037948897.HKD","LU1066051811.HKD","IE00B19Z3581.USD","LU1116320901.HKD","LU1934455277.USD","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU0208291251.USD","IE00B3T34201.USD","PD","GILD","LU1061106388.HKD","BK4568","MRK"],"gpt_icon":0},{"id":"2538544575","title":"吉利德走出水逆？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538544575","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538544575?lang=zh_cn&edition=full","pubTime":"2025-05-28 13:35","pubTimestamp":1748410505,"startTime":"0","endTime":"0","summary":"2024年，吉利德堪称水逆王者。更紧迫的是，吉利德必须尽快突破乳腺癌的“舒适区”。Trodelvy在肺癌领域的失利阴影尚未消散，而小细胞肺癌、子宫内膜癌等新战场的开拓能否成功，将决定其能否真正走出水逆。4月21日，吉利德宣布，Trodelvy+K药联合一线治疗转移性三阴乳腺癌的ASCENT-04试验获得成功。/ 02 / TNBC攻防战2025年一季度，Trodelvy的销售额出现了下滑，尽管吉利德表示这是库存调整所导致的，但市场竞争的压力不言而喻。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052813350997681163&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052813350997681163&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU0320765489.SGD","LU1934455863.HKD","LU0965509283.SGD","LU1066051811.HKD","BK4139","IE00BKVL7J92.USD","MRK","LU0211331839.USD","LU0320765646.SGD","LU0265550946.USD","LU0070302665.USD","LU0266013472.USD","SG9999002224.SGD","GILD","LU1066053197.SGD","BK4568","LU1839511570.USD","IE00BBT3K403.USD","LU1116320737.USD","SG9999015341.SGD","BK4588","LU0265550359.USD","LU1674673691.USD","LU0965509101.SGD","BK4211","IE00BN8TJ469.HKD","IE00B2B36J28.USD","BK4534","LU1989772923.USD","BK4516","L","LU1093756168.USD","LU0965508806.USD","LU1989771016.USD","LU1116320901.HKD","LU0985320562.USD","LU2023250504.SGD","LU1023059063.AUD","IE0002270589.USD","LU1066051225.USD","BK4007","IE00B7SZLL34.SGD","IE00BJJMRZ35.SGD","LU1941712264.USD","LU0889565916.HKD","LU1974910355.USD","PFS","SG9999014575.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"2538211551","title":"艾伯维挥起拳头","url":"https://stock-news.laohu8.com/highlight/detail?id=2538211551","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538211551?lang=zh_cn&edition=full","pubTime":"2025-05-25 10:59","pubTimestamp":1748141979,"startTime":"0","endTime":"0","summary":"艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！表1.艾伯维免疫领域核心产品这一颓势直接拖累艾伯维2024年净利润下跌12.03%。表2.艾伯维肿瘤领域核心产品然而，随着百济神州的泽布替尼、阿斯利康的阿卡替尼等二代BTK抑制剂通过“头对头”试验证明更优疗效与安全性，伊布替尼市场份额被快速瓜分。02频繁动刀为了走出“泥潭”，艾伯维在肿瘤领域多次挥刀，转而瞄准自免与神经科学等赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4097","IE00BGHQF631.EUR","IBD","IE00BDGV0183.EUR","LU0203347892.USD","LU0234572021.USD","LU0310800379.SGD","LU1585245621.USD","LU1934455863.HKD","LU1983299246.USD","LU2087621335.USD","SG9999015945.SGD","IE00B4R5TH58.HKD","LU1244550221.USD","SG9999003800.SGD","LU0912757837.SGD","LU2237443382.USD","LU0965509101.SGD","IE00B19Z3B42.SGD","LU1551013425.SGD","SG9999015986.USD","ABBV","IE00BVYPNV92.GBP","LU0861579265.USD","IE0002270589.USD","LU1093756325.SGD","LU0949170772.SGD","LU2129689605.HKD","ORR","BK4093","LU2237443895.HKD","LU2112291526.USD","OS","LU0122379950.USD","LU1244550577.SGD","LU0211327993.USD","PFS","SG9999015952.SGD","LU0820561909.HKD","BK4566","CF","IE0009355771.USD","LU0029864427.USD","LU1162221912.USD","LU1244550494.USD","IE00B3PB1722.GBP","LU1989772923.USD","PROC","LU2133065610.SGD","BK4139"],"gpt_icon":0},{"id":"2537976421","title":"科济药业舒瑞基奥仑赛注射液（CT041）的摘要已公布于ASCO网站","url":"https://stock-news.laohu8.com/highlight/detail?id=2537976421","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537976421?lang=zh_cn&edition=full","pubTime":"2025-05-23 08:00","pubTimestamp":1747958400,"startTime":"0","endTime":"0","summary":"关于舒瑞基奥仑赛注射液舒瑞基奥仑赛注射液是一款潜在全球同类首创的、靶向Claudin18.2蛋白的自体CAR-T细胞治疗候选产品，用于治疗Claudin18.2阳性实体瘤，主要治疗胃癌/食管胃结合部腺癌及胰腺癌。2020年9月，舒瑞基奥仑赛注射液被美国FDA授予\"孤儿药\"认定用于治疗胃癌/食管胃结合部腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4694213_ZH94213_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4195","IE00B66KJ199.SGD","LU2065731478.USD","CRS","BK1585","BK4006","BK1574","BK4213","TPC","BK4022","BK4097","IE0031619046.USD","SOC","BK1587","CAR","BK4230","IE00B7SZL793.SGD","BK1161","02171","PFS","IE00B19Z4B17.USD","OS","BK4211","BK4129"],"gpt_icon":0},{"id":"2535538289","title":"中国多中心研究探索奥雷巴替尼治疗慢性期CML的优化剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=2535538289","media":"亿欧网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535538289?lang=zh_cn&edition=full","pubTime":"2025-05-16 10:08","pubTimestamp":1747361330,"startTime":"0","endTime":"0","summary":"一项多中心回顾性研究通过倾向性评分匹配比较了奥雷巴替尼40mg隔日一次和30mg QOD起始剂量在慢性髓性白血病患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例。经过PSM调整后，两组基线协变量相似。相比之下，40mg QOD组在这些指标上的表现略低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ky.jrj.com.cn/2025/05/16100850435864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["OS","PSM","CHR","PFS","BK4195","BK4077","BK4211","BK4097"],"gpt_icon":0},{"id":"2534271890","title":"公积金金融服务盘中异动 股价大涨5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534271890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534271890?lang=zh_cn&edition=full","pubTime":"2025-05-12 21:32","pubTimestamp":1747056733,"startTime":"0","endTime":"0","summary":"北京时间2025年05月12日21时32分，公积金金融服务股票出现波动，股价大幅上涨5.67%。截至发稿，该股报18.08美元/股，成交量2.878万股，换手率0.02%，振幅0.35%。公积金金融服务股票所在的银行行业中，整体涨幅为1.99%。该公司的业务仅限于金融服务行业，包括向客户提供传统银行和其他金融服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213213a47b76ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213213a47b76ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2532859276","title":"康宁杰瑞制药-B现涨超12% HER2双抗KN026临床研究期中分析达PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532859276","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532859276?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:50","pubTimestamp":1746150600,"startTime":"0","endTime":"0","summary":"　　康宁杰瑞制药-B盘中涨超12%，截至发稿，股价上涨12.07%，现报7.24港元，成交额1319.95万港元。　　康宁杰瑞生物制药与石药集团共同宣布，HER2双特异性抗体KN026联合化疗二线及以上治疗HER2阳性胃癌的Ⅱ/Ⅲ期临床研究已完成首次期中分析，经独立数据监察委员会评估，达到预先设定的无进展生存期的主要终点，具有统计学显著性和临床意义。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-05-02/doc-inevctpe5151918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","PFS","BK4195","09966","BK4211"],"gpt_icon":0},{"id":"2532856051","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超12% HER2双抗KN026临床研究期中分析达PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532856051","media":"智通财经","labels":["executive","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532856051?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:38","pubTimestamp":1746149889,"startTime":"0","endTime":"0","summary":"消息面上，康宁杰瑞生物制药与石药集团共同宣布，HER2双特异性抗体KN026联合化疗二线及以上治疗HER2阳性胃癌的Ⅱ/Ⅲ期临床研究已完成首次期中分析，经独立数据监察委员会评估，达到预先设定的无进展生存期的主要终点，具有统计学显著性和临床意义。该产品国内权益已出售给石药集团，首付款与里程碑总计10 亿元，双位数销售分成。目前其临床结果十分优秀，与多西他赛联用治疗HER2 阳性BC 的PFS 为 27.7 个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","PFS","BK4211","09966","BK4195","BK1161"],"gpt_icon":0},{"id":"2532701570","title":"HER2双抗KN026关键性Ⅱ/Ⅲ期临床研究期中分析达到PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2532701570","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532701570?lang=zh_cn&edition=full","pubTime":"2025-05-01 09:41","pubTimestamp":1746063660,"startTime":"0","endTime":"0","summary":"苏州 2025年5月1日 /美通社/ --康宁杰瑞生物制药与石药集团共同宣布，HER2双特异性抗体KN026联合化疗二线及以上治疗HER2阳性胃癌的Ⅱ/Ⅲ期临床研究已完成首次期中分析，经独立数据监察委员会评估，达到预先设定的无进展生存期的主要终点，具有统计学显著性和临床意义。目前针对二线及以上HER2阳性胃癌/胃食管结合部癌、一线HER2阳性乳腺癌、HER2阳性乳腺癌新辅助等适应症的多项注册临床研究正在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4677725_ZH77725_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK4195","BK4211","BK1574","PFS","09966"],"gpt_icon":0},{"id":"2531030234","title":"石药集团(01093)：KN026关键性II╱III期临床研究的期中分析达到无进展生存期(PFS)主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2531030234","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531030234?lang=zh_cn&edition=full","pubTime":"2025-04-30 21:23","pubTimestamp":1746019419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，公司附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司合作开发的KN026用于至少接受过一种系统性治疗失败的HER2阳性局部晚期、复发或转移性的胃癌受试者的关键性II╱III期临床研究，经独立数据监察委员会评估，达到预先设定的无进展生存期的主要终点，具有统计学显著性和临床意义。本次计划的期中分析的主要目的是对经IRC评估的PFS进行有效性分析。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091754.HKD","LU1226288253.USD","III","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","BK1515","LU1226288170.HKD","IE00B031HY20.USD","LU0880133367.SGD","LU1960683339.HKD","LU0501845795.SGD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU0072913022.USD","LU1807302812.USD","BK1191","BK4134","LU1993786604.SGD","LU0140636845.USD","LU0326950275.SGD","LU1226287529.USD","BK1521","BK4211","BK4195","IE0008369823.USD","LU1152091168.USD","01093","LU1008478684.HKD","SG9999004220.SGD","LU1226287792.SGD","IE00BZ08YS42.EUR","IE0008368742.USD","PFS","IE00B543WZ88.USD","LU0067412154.USD","LU1226287875.USD"],"gpt_icon":0},{"id":"2531035965","title":"康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035965","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531035965?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:30","pubTimestamp":1746012652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，本公司与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的KN026联合化疗二线及以上治疗HER2阳性GC的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001研究第2部分的首个PFS期中分析结果已由独立数据监察委员会 审查，结果显示达到预先设定的PFS的主要终点，具有统计学显著性和临床意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4211","BK4195","09966","III","BK1574","PFS","BK1576","BK1141","BK4134","BK1161","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.1169},{"period":"3month","weight":0.178},{"period":"6month","weight":0.0075},{"period":"1year","weight":0.3116},{"period":"ytd","weight":-0.0074}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.1307},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.1172},{"period":"ytd","weight":0.0585}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.028152},{"month":2,"riseRate":0.391304,"avgChangeRate":-0.014563},{"month":3,"riseRate":0.434783,"avgChangeRate":-0.003684},{"month":4,"riseRate":0.478261,"avgChangeRate":0.005908},{"month":5,"riseRate":0.478261,"avgChangeRate":-0.011563},{"month":6,"riseRate":0.478261,"avgChangeRate":-0.000381},{"month":7,"riseRate":0.652174,"avgChangeRate":0.041698},{"month":8,"riseRate":0.5,"avgChangeRate":-0.010154},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.016983},{"month":10,"riseRate":0.681818,"avgChangeRate":0.035845},{"month":11,"riseRate":0.681818,"avgChangeRate":0.032932},{"month":12,"riseRate":0.545455,"avgChangeRate":0.012415}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}